Biopharmaceutical company developing oncology drugs that target epigenetic regulators
Biopharmaceutical company developing oncology drugs that target epigenetic regulators. Its pipeline included small-molecule inhibitors of EZH2 and bromodomain and extra-terminal (BET) proteins, with candidates for myelofibrosis and other blood cancers and solid tumors. Acquired by MorphoSys in 2021.